Hoi-Yoon Jung
Algemeen Directeur bij NOVMETAPHARMA CO., LTD.
Profiel
Hoi-Yoon Jung is currently the Co-CEO, Director & Head-Research at NovMetaPharma Co., Ltd.
and the Research & Development Director at NovMetaHealth Co. Ltd.
Additionally, he is a Professor at Pohang University of Science & Technology since 2019.
He holds a doctorate degree from Pohang University of Science & Technology and undergraduate and graduate degrees from Handong Global University.
Actieve functies van Hoi-Yoon Jung
| Bedrijven | Functie | Begin |
|---|---|---|
| NOVMETAPHARMA CO., LTD. | Algemeen Directeur | - |
NovMetaHealth Co. Ltd.
 NovMetaHealth Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of NovMetaPharma Co., Ltd., NovMetaHealth Co. Ltd. develops and manufactures products related to metabolic diseases. The company is based in Seoul, South Korea. The South Korean company was founded in 2016. Seon-Wook Hwang has been the CEO of the company since 2016. NovMetaHealth Co. was acquired by NovMetaPharma Co., Ltd. on March 10, 2022 for $12.61 million. | Hoofd Techniek/Wetenschap/O&O | - |
| Pohang University of Science & Technology | Corporate Officer/Principal | 01-01-2019 |
Opleiding van Hoi-Yoon Jung
| Handong Global University | Graduate Degree |
| Pohang University of Science & Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| NOVMETAPHARMA CO., LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
NovMetaHealth Co. Ltd.
NovMetaHealth Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of NovMetaPharma Co., Ltd., NovMetaHealth Co. Ltd. develops and manufactures products related to metabolic diseases. The company is based in Seoul, South Korea. The South Korean company was founded in 2016. Seon-Wook Hwang has been the CEO of the company since 2016. NovMetaHealth Co. was acquired by NovMetaPharma Co., Ltd. on March 10, 2022 for $12.61 million. | Health Technology |
